Crossmark

Combination therapy with protein kinase inhibitor H89 and Tetrandrine elicits enhanced synergistic antitumor efficacy

Crossref DOI link: https://doi.org/10.1186/s13046-018-0779-2

Published Online: 2018-06-04

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yu, Man

Liu, Ting

Chen, Yicheng

Li, Yafang

Li, Wenhua
Funding

Funding for this research was provided by:

The National Basic Research Program of China (2014CB910600)

The National Natural Science Foundation of China (81273540 and 81472684)

Fundamental Research Funds for the Central Universities (2042017KF0242)
License Information

Text and Data Mining valid from 2018-06-04
More Information

Article History

Received: 23 March 2018

Accepted: 21 May 2018

First Online: 4 June 2018

Ethics approval and consent to participate

: For the animal study, all animal care and experiments were approved by the Experimental Animal Center of Wuhan University.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.